The changing diagnostic pathway for lung cancer patients in Shanghai, China
- 17 August 2017
- journal article
- review article
- Published by Elsevier BV in European Journal of Cancer
- Vol. 84, 168-172
- https://doi.org/10.1016/j.ejca.2017.07.036
Abstract
No abstract availableFunding Information
- National Natural Science Foundation of China (81402486)
- RMH BRC
- NHS
- NIHR UK
- IASLC
This publication has 17 references indexed in Scilit:
- Cancer statistics in China, 2015CA: A Cancer Journal for Clinicians, 2016
- TGF-β1/FGF-2 signaling mediates the 15-HETE-induced differentiation of adventitial fibroblasts into myofibroblastsLipids in Health and Disease, 2016
- Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6The Lancet Oncology, 2015
- High Discrepancy of Driver Mutations in Patients with NSCLC and Synchronous Multiple Lung Ground-Glass NodulesJournal of Thoracic Oncology, 2015
- Crizotinib in ROS1-Rearranged Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2014
- ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: A comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic featuresLung Cancer, 2014
- Recent advances in immunotherapy for non-small-cell lung cancerHuman Vaccines & Immunotherapeutics, 2013
- ROS1 fusions in Chinese patients with non-small-cell lung cancerAnnals of Oncology, 2013
- Crizotinib versus Chemotherapy in AdvancedALK-Positive Lung CancerThe New England Journal of Medicine, 2013
- KIF5B‐RET fusions in Chinese patients with non–small cell lung cancerCancer, 2013